ライフサイエンスコーパス: bone lesion

1 lymph node lesions, 27 liver lesions, and 50 bone lesions).

2 (hypercalcaemia, renal failure, anaemia, and bone lesions).

3 ic MM is a well-demarcated, focal osteolytic bone lesion.

4 d bone colonization and decreased osteolytic bone lesions.

5 lving extramedullary hematopoiesis, skin and bone lesions.

6 y Medical Center Groningen were reviewed for bone lesions.

7 ons exhibit defective osteoclastogenesis and bone lesions.

8 reviewed to identify patients with malignant bone lesions.

9 of tumor cells to the bone marrow and lytic bone lesions.

10 could be used to detect osteoclasts in lytic bone lesions.

11 of bone tumors with no development of lytic bone lesions.

12 teoblastic character of most prostate cancer bone lesions.

13 d were associated with the presence of focal bone lesions.

14 contrast, only 4% of beta3-/- mice developed bone lesions.

15 eloma (MM) is commonly associated with lytic bone lesions.

16 mpared with other forms of therapy for lytic bone lesions.

17 or RANKL, prevented the development of lytic bone lesions.

18 ation, and radiologic evidence of osteolytic bone lesions.

19 logies in 15 specimens, including 10 primary bone lesions.

20 nd inhibition of radiographic progression of bone lesions.

21 e not significantly different from those for bone lesions.

22 nohistochemistry was performed on metastatic bone lesions.

23 tures from other processes such as malignant bone lesions.

24 rum M spikes, bone marrow insufficiency, and bone lesions.

25 vator (CIITA) contributes to myeloma-induced bone lesions.

26 tiorgan secondary metastases that arise from bone lesions.

27 as dramatically upregulated in AR-V7-induced bone lesions.

28 y Medical Center Groningen were reviewed for bone lesions.

29 r the initial assessment of MM-related lytic bone lesions.

30 aracterized by the development of osteolytic bone lesions.

31 ifests with bone marrow tumors causing lytic bone lesions.

32 associated with osteoporosis and metastatic bone lesions.

33 d NOS (not otherwise specified), nonspecific bone lesions.

34 sound diathermy may be associated with focal bone lesions.

35 tricle, leading to disseminated visceral and bone lesions.

36 een osteoclasts and osteoblasts and leads to bone lesions.

37 properties on cancer cells disseminated from bone lesions.

38 cycle by 27% for lymph nodes and by 33% for bone lesions.

39 erozygous mice; none of these mice developed bone lesions.

40 ial advantages over PET/CT for evaluation of bone lesions.

41 T for anatomic delineation and allocation of bone lesions.

42 ntification was reduced by a factor of 4 for bone lesions (10.24% for Dixon PET and 2.68% for ZeDD PE

43 re found for PET/MR than for PET/CT both for bone lesions (12.4% +/- 15.5%) and for regions of normal

44 ate liver lesions, 2 patients with sclerotic bone lesions, 2 patients with breast abnormalities, 1 pa

45 Results: Overall, 98 IBLs within 267 bone lesions (36.7%) were identified in 48 of 243 patien

46 er sensitivity than MRI or (18)F-FDG PET for bone lesions (95.8% vs. 90.7% and 89.3%, respectively).

47 ditions, AR-V7 strongly induced osteoblastic bone lesions, a response not observed with AR-FL overexp

48 of hematopoiesis and formation of osteolytic bone lesions also known as myeloma bone disease (MBD).

49 Lesions were scored on CT and bone lesions also on SRS before and after treatment.

50 nt, mimicking progressive disease with "new" bone lesions, although there was an overall treatment re

51 Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multip

52 ith breast cancer who had at least one lytic bone lesion and who were receiving hormonal therapy were

53 (11)C-acetate-avid and (18)F-FDG-avid focal bone lesions and (11)C-acetate general marrow activity-s

54 The RC was +/-32.5% SUV(max) for bone lesions and +/-37.9% SUV(max) for nodal lesions, me

55 The RC was +/-32.5% SUV(max) for bone lesions and +/-37.9% SUV(max) for nodal lesions, me

56 The wCV for SUV(max) was 11.7% for bone lesions and 13.7% for nodes.

57 choline-avid metastases were identified: 44 bone lesions and 23 lymph node lesions.

58 Yield was 87% for lytic bone lesions and 57% for sclerotic bone lesions (P = .00

59 In total, 30 bone lesions and 60 soft-tissue lesions were evaluated.

60 Diagnostic yield was 77% for bone lesions and 76% for soft-tissue lesions (P = .88).

61 analyzed by ex vivo 3-dimensional imaging of bone lesions and by proteomic analysis and were further

62 by PCs correlates with the presence of lytic bone lesions and distinguishes MM from reactive plasmacy

63 ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in

64 2.8 mo) in the 19 patients who showed no new bone lesions and final TLA lower than the median of 750

65 it reached a plateau at three specimens for bone lesions and four specimens for soft-tissue lesions.

66 Obtaining a minimum of three specimens in bone lesions and four specimens in soft-tissue lesions o

67 ibuting factor to the increase in osteolytic bone lesions and hypercalcemia found in ATL patients.

68 acute ATL patients is the presence of lytic bone lesions and hypercalcemia.

69 ow plasma cells characterized by destructive bone lesions and is fatal in most patients.

70 ination of tumor cells leading to osteolytic bone lesions and liver metastases, common sites of clini

71 etal coccidioidomycosis manifests with lytic bone lesions and may produce peripherally enhancing flui

72 Patients with 1 to 3 bone lesions and negative bone marrows are often treated

73 o significantly different between metastatic bone lesions and normal-appearing bone tissue (P <= .02)

74 th paclitaxel would inhibit experimental FTC bone lesions and preserve bone structure.

75 For bone lesions and regions of normal bone, a highly signif

76 lary disease, as well as the number of focal bone lesions and SUV(max), has been reported in several

77 IL-1 signaling can cause aseptic osteolytic bone lesions and that the absence of IL-10 signaling cau

78 hatase to confirm the presence of osteolytic bone lesions and the presence of osteoclasts, respective

79 e useful in yielding the precise location of bone lesions and thus helping avoid misdiagnosis of bone

80 integrated (18)F-FDG PET/MR specifically for bone lesions and to analyze differences in standardized

81 entiating between benign and malignant focal bone lesions and to propose a Bone Tumor Imaging Reporti

82 cer type, chemotherapy status, and number of bone lesions and were compared by using Fisher exact tes

83 yeloma-induced bone loss, reduced osteolytic bone lesions, and increased fracture resistance.

84 lonal gammopathy, BM infiltration with lytic bone lesions, and protein deposition in the kidney.

85 mponents: diffuse marrow infiltration, focal bone lesions, and soft-tissue (extramedullary) disease.

86 docrinopathy, skin changes, edema, sclerotic bone lesions, and thrombocytosis.

87 (18)F-DCFBC PET detection of lymph nodes, bone lesions, and visceral lesions was superior to CIM.

88 aemia, renal failure, anaemia, or osteolytic bone lesions-and a detailed diagnostic investigation is

89 gnosis should be considered when superficial bone lesions appear time-related to therapy and in areas

90 The present study demonstrates that NOMID bone lesions are derived from the same osteoblast progen

91 tasis burden but becomes less effective when bone lesions are well established.

92 e metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteoclasts at t

93 astasis, treatment with GANT58-NPs decreased bone lesion area by 49% (p<.01) and lesion number by 38%

94 lveolar processes for presence of osteolytic bone lesions around causative teeth roots and we found t

95 ficant decrease in the incidence and size of bone lesions as compared with the results in control or

96 rP may reduce the development of destructive bone lesions as well as the growth of tumor cells in bon

97 s (PC3-AR9) results in decreased invasion in bone lesion assays and in vivo mouse models.

98 compared management recommendations based on bone lesion assessment by (18)F-FDG PET plus contrast-en

99 GE2 inhibition may be therapeutic targets in bone lesions associated with defects of these two pathwa

100 2) evaluable men had at least one responding bone lesion at PET3 using QTBI.

101 acid; 0.77, 0.65-0.92; p=0.0038) and without bone lesions at baseline (29 [10%] of 302 vs 48 [17%] of

102 Conclusion: The number of sclerotic bone lesions at body CT is of potential value in the dia

103 and PET-CT with respect to the detection of bone lesions at diagnosis and the prognostic value of th

104 The primary end point was the detection of bone lesions at diagnosis by MRI versus PET-CT.

105 n There is no difference in the detection of bone lesions at diagnosis when comparing PET-CT and MRI.

106 ved were ganglia, unspecific lymph node, and bone lesions, at a rate of 43%, 31%, and 24% for (18)F-P

107 ercalcemia, renal failure, anemia, and lytic bone lesions attributable to clonal expansion of plasma

108 In 1 patient, bone lesions became visible on CT after treatment, mimic

109 d nonpigmented schwannomas and fibro-osseous bone lesions beginning at approximately 6 months of age.

110 coisolated with N-type cells from metastatic bone lesions, but to date their ability to induce cooper

111 Our current approach to quantify metastatic bone lesions, called the Bone Scan Index, is based on an

112 icance, additional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphad

113 by PCs correlated with the presence of lytic bone lesions (chi-square, 33.39: P <0.000; odds ratio, 1

114 ed prevalence of knee OA-related subchondral bone lesions compared with those reporting no use of the

115 sensitive for bone metastases, detecting 341 bone lesions, compared with 246 by conventional imaging.

116 The risk for osteolytic bone lesion complications in metastatic breast cancer wa

117 most of the patients have revealed the mixed bone lesions, comprising both osteolytic and osteoblasti

118 The number of focal bone lesions correlates inversely with outcome.

119 vaccines in reference to the development of bone lesions currently exist.

120 ally and clinically robust for evaluation of bone lesions despite differences in attenuation correcti

121 Multiple sites of focal bone lesions detected on MR studies allow a more appropr

122 lobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be

123 knockout significantly decreased MDA-MB-231 bone lesion development in both the cardiac and tibial i

124 The mechanism by which bFGF rescued the bone lesion development was by promotion of tumor cell p

125 Metastatic bone lesion development was compared by analysis of both

126 ons that facilitate tumor growth and control bone lesion development.

127 br2 KO mice rescued the inhibited metastatic bone lesion development.

128 tivariate predictors: SPECT detection of new bone lesions during treatment (P < 0.0001) and final SPE

129 h use of imaging to assess whether sclerotic bone lesions, effusions, and organomegaly are present.

130 ND FINDINGS: Fifty-eight adult patients with bone lesions, either as a solitary site or as a componen

131 in acts as an important determinant in mixed bone lesions, especially in controlling osteoblastic eff

132 ant differences in activity were seen in the bone lesion evaluated on the baseline and initial postal

133 Purpose: To determine if sclerotic bone lesions evident at body computed tomography (CT) ar

134 one scan plus CT detected an equal number of bone lesions for 14 patients (64%), PSMA PET/CT detected

135 14 patients (64%), PSMA PET/CT detected more bone lesions for six patients (27%), and bone scan plus

136 s (27%), and bone scan plus CT detected more bone lesions for two patients (9.1%) (p = 0.092).

137 skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV bre

138 ion of prostate cancer metastases, including bone lesions for which there is no current reliable agen

139 a(+/-) and Prkar1a(+/-)Prkar2b(+/-) animals, bone lesions formed that looked like those of the Prkar1

140 immune evasion and play an essential role in bone lesions frequently found in MM patients.

141 of skeletal-related events in patients with bone lesions from multiple myeloma.

142 ET-derived SUV imaging metrics in individual bone lesions from patients in a multicenter study.

143 new bone formation is frequently seen in the bone lesions from prostate cancer.

144 sed by 70% in anti-CCL2-treated animals with bone lesions from VCaP cells.

145 Finally, patients with bone lesions had relatively higher levels of M-CSF and o

146 In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P = .01), high IS

147 of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and comp

148 Indeterminate bone lesions (IBLs) on prostate-specific membrane antige

149 corresponding CT morphology features of 146 bone lesions identified in these 25 patients were follow

150 n species of Penicillium was isolated from a bone lesion in a young dog with osteomyelitis of the rig

151 a-PSMA-11 PET/CT imaging revealed additional bone lesions in 6% of patients, but without significantl

152 FPyL PET, whereas (18)F-DCFPyL PET localized bone lesions in 8 of 38 (21%) patients with negative res

153 ective and minimally toxic treatment for LCH bone lesions in adults.

154 old woman presented with bone pain and lytic bone lesions in April 2010.

155 etic role in the establishment of osteolytic bone lesions in breast cancer.

156 The majority of metastatic bone lesions in cervical cancer seem to be of osteolytic

157 hough IL-1beta is known as the key driver of bone lesions in CRMO, the signaling events leading to pa

158 t is unknown whether assessment of potential bone lesions in metastatic breast cancer (MBC) by (18)F-

159 y, and its serum level correlates with focal bone lesions in MM.

160 ondin1 (RSpo1) were sufficient to repair the bone lesions in multiple myeloma and rheumatoid arthriti

161 Th1 phenotype may profoundly diminish lytic bone lesions in multiple myeloma.

162 s (MILs) in OC activation and development of bone lesions in myeloma patients.

163 icantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice.

164 a primary imaging modality for assessment of bone lesions in newly diagnosed MBC.

165 tal complications associated with osteolytic bone lesions in patients with breast cancer and multiple

166 lls is associated with the presence of lytic bone lesions in patients with multiple myeloma.

167 ive therapeutic approach to treat osteolytic bone lesions in patients with myeloma.

168 mor-induced bone gain, a response resembling bone lesions in prostate cancer patients.

169 igher doses were achieved for lymph node and bone lesions in responders.

170 luation Criteria in Solid Tumors (RECIST) or bone lesions in the absence of measurable disease, witho

171 K-1, or MCP-1 were each sufficient to reduce bone lesions in vivo.

172 cancer cell lines in vitro and in metastatic bone lesions in vivo.

173 normal tissue and metastatic prostate cancer bone lesions in vivo.

174 c yield is higher in lytic than in sclerotic bone lesions, in larger lesions, and for longer specimen

175 Whereas bone lesions increased in size, soft-tissue lesions decr

176 lesions that closely mirror the osteoblastic bone lesions induced by metastatic prostate tumors in hu

177 Strong TGF-beta signaling in osteolytic bone lesions is suppressed directly by genetic and pharm

178 opoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved programmed

179 for uncontrolled growth causing destructive bone lesions, kidney injury, anemia, and hypercalcemia.

180 A total of 411 bone lesions larger than 1.5 cm(3) were automatically se

181 T imaging allowed high-contrast detection of bone lesions, lymph node, and liver metastases.

182 most organs was higher than zero, except for bone lesions (mean DDR, -2.8%; 95% CI, -17.8 to 12.2).

183 Sixteen bone lesions (midtibia, n = 14; distal fibula, n = 1; an

184 cells that manifests as one or more of lytic bone lesions, monoclonal protein in the blood or urine,

185 less than 5% for soft tissue and in or near bone lesions (n = 91).

186 e important in the hypercalcemia, osteolytic bone lesions, neutrophilia, elevation of C-reactive prot

187 myeloma (MM) is characterized by osteolytic bone lesions (OBL) that arise as a consequence of osteob

188 3 years) with a confirmed malignant solitary bone lesion of maximum dimension of 8 cm or smaller that

189 We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal p

190 nt had no significant effect on cartilage or bone lesions of OA.

191 oportion of men with at least one responding bone lesion on PET3 using QTBI.

192 Additional bone lesions on (18)F-FDG PET plus ceCT compared with BS

193 able disease (91%), and/or appearance of new bone lesions on bone scan (83%).

194 herapy, regardless of presence of osteolytic bone lesions on conventional radiography.

195 ize of bone lesions or the appearance of new bone lesions on CT after treatment with (177)Lu-octreota

196 We have noted that bone lesions on CT respond differently from soft-tissue

197 ration-resistant prostate cancer, numbers of bone lesions on CT, FDG PET, and FDHT PET scans and the

198 ho had atypically distributed, purely cystic bone lesions on CT; measuring the Hounsfield (HU) of the

199 The intensity or number of bone lesions on SRS decreased after treatment in 19 of 2

200 Bone lesions on the spine of a male skeleton excavated a

201 clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive dissemi

202 with NETs, the apparent increase in size of bone lesions or the appearance of new bone lesions on CT

203 major criteria (Castleman disease, sclerotic bone lesions, or elevated VEGF) and at least one minor c

204 ependent of the number of syndrome features, bone lesions, or plasma cells at diagnosis.

205 han FDG-PET overall and for the detection of bone lesions (P < .001).

206 for lytic bone lesions and 57% for sclerotic bone lesions (P = .002).

207 bgroup of patients with metabolically active bone lesions (P = 0.02), but no difference was highlight

208 Improvement in bone lesions, pain, diabetes insipidus, and other manife

209 ling pathway has a significant impact on the bone lesion phenotype.

210 logy, growth pattern, and development of new bone lesions, possible bone metastases were classified a

211 ow, but the generalized osteopenia and focal bone lesions present in many adult patients are refracto

212 A high correlation between bone lesion quantity as determined visually and automati

213 are pustular rash, marked osteopenia, lytic bone lesions, respiratory insufficiency, and thrombosis.

214 patients, (18)F-FDG PET versus BS to assess bone lesions resulted in clinically relevant management

215 For bone lesions, significant underestimations of -16% and -

216 Bone lesion SIR was significantly higher on signal-contr

217 n on normal tissue, soft-tissue lesions, and bone lesions; standardized uptake values were quantitati

218 tect highly significant progression of lytic bone lesions, subchondral sclerosis, and osteophyte size

219 g to multiple neoplasias, is associated with bone lesions such as osteochondromyxomas (OMX).

220 pathologies, effusion, tendon, cartilage and bone lesions, tendon and ligament pathology at the site

221 ty in an orthotopic model of diffuse myeloma bone lesions than in conventional subcutaneous xenograft

222 ysmal bone cyst (ABC) is a locally recurrent bone lesion that has been regarded as a reactive process

223 as the rhizomelic dwarfism and nonossifying bone lesions that are characteristic of the disorder.

224 nted patients develop osteoporosis and other bone lesions that are related, at least in part, to thei

225 Prostate cancer (CaP) develops metastatic bone lesions that consist of a mixture of osteosclerosis

226 ession of MVNP (MVNP mice) developed PD-like bone lesions that required MVNP-dependent induction of h

227 plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and cl

228 f protein kinase A (PKA) activity, developed bone lesions that were derived from cAMP-responsive oste

229 m) and malignant lesions (pulmonary nodules, bone lesions); the regression line was y = 0.85x + 0.15,

230 In bone lesions, the average underestimation was -7.4% +/-

231 lay a major role in the development of lytic bone lesions, the major clinical feature distinguishing

232 For bone lesions, the respective mean doses were 3.47 +/- 2.

233 ma, extravascular volume overload, sclerotic bone lesions, thrombocytosis, elevated VEGF, and abnorma

234 We report three cases of focal bone lesions time-related with physiotherapy using ultra

235 The signal intensity ratio (SIR) of bone lesions to normal-appearing bone was measured on th

236 t the spread of metastatic cancer cells from bone lesions to other organs.

237 l for clinically quantifying the response of bone lesions to therapy.

238 zed the responses of adult LCH patients with bone lesions to three primary chemotherapy treatments to

239 In this model, bone lesions typical of the human disease develop in mic

240 For bone lesions, underestimation of PET standardized uptake

241 ce (P < 0.01) in the ratio of lymph node and bone lesion uptake to kidney uptake between responders a

242 ating osteoclast activity within deep-seated bone lesions using appropriate fluorescent probes, despi

243 we established a novel mouse model of mixed bone lesions using intratibial injection of TM40D-MB cel

244 how PSTPIP2 deficiency causes osteopenia and bone lesions, using the mouse PSTPIP2 mutations, cmo, wh

245 m one to the other class identified apparent bone lesion volume change (Delta BLV).

246 Bone lesion was evaluated by Tartrate-resistant acid pho

247 The median number of bone lesions was 1 (range: 1-6).

248 The detection rate for all bone lesions was 35% (247 of 698) for MPRs and 74% (520

249 Mean (95% CI) displacement of bone lesions was 6.0 mm (95% CI 5.0-7.2); maximum displa

250 The accuracy in diagnosing bone lesions was 89.7% for planar bone scanning versus 9

251 presence or absence of metabolically active bone lesions was also recorded for each patient, and pat

252 The critical role of PD-1H in myeloma lytic bone lesions was confirmed using a Pd-1h(-/-) myeloma bo

253 rence in correct classification of malignant bone lesions was found among sets A (85/90), B (84/90),

254 To address how Notch affects prostate cancer bone lesions, we manipulated Notch expression in mouse t

255 oxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90

256 three patient groups Four or more sclerotic bone lesions were detected in all 25 (100%) of those wit

257 Lytic bone lesions were detected using x-rays in all the hyper

258 If no bone lesions were found by any imaging modality, the pat

259 If bone lesions were found by any imaging modality, virtual

260 PSMA-positive bone lesions were found in 105 of 388 (27%) patients, wi

261 Results: In total, 3,473 unequivocal bone lesions were identified in 102 evaluated patients (

262 In total, 98 bone lesions were identified in 33 of 119 patients, and

263 Notably, bone lesions were identified in 8.8% of patients (9/102)

264 Most bone lesions were in the skull, spine, or jaw.

265 Because bone lesions were not visible on CT before treatment in

266 Bone lesions were present in 40 of the 51 MM patients an

267 Solitary bone lesions were reported on 21 radiographic surveys an

268 Results: Most commonly the sclerotic bone lesions were round, measured 0.3 cm (range, 0.2-3.2

269 Subcutaneous and lytic bone lesions were strongly associated with B. quintana,

270 aphy (CT) in the identification of malignant bone lesions when the PET and CT findings are discordant

271 Specifically, osteolytic bone lesions, where bone is destroyed, lead to debilitat

272 ased the capacity of the cells to repair the bone lesion, whereas BIO treatment had no significant ef

273 ng hypercalcemia, renal failure, anemia, and bone lesions, whereas MGUS and smoldering myeloma are di

274 n bone disease and is characterized by focal bone lesions which contain large numbers of abnormal ost

275 been described in both benign and malignant bone lesions, which can lead to false-positive findings

276 ancer (BCa) bone metastases cause osteolytic bone lesions, which result from the interactions of meta

277 r and area of radiographically evident lytic bone lesions, which, at the highest dose, were undetecta

278 omen with metastatic breast cancer and lytic bone lesions who received chemotherapy were randomly ass

279 s or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines o

280 r flare (eg, >5 sites of visceral disease or bone lesions with impending fracture).

281 The P394L mutant mice developed focal bone lesions with increasing age and by 12 months, 14/18

282 d shape, size, and distribution of sclerotic bone lesions with subsequent calculation of differences

283 We therefore compared the response of bone lesions with that of soft-tissue lesions to treatme

284 myeloma (MM) is characterized by osteolytic bone lesions with uncoupled bone remodeling.